Stifel cuts DBV Technologies to hold; PT $11

Stifel downgraded DBV Technologies (NASDAQ:DBVT) to “hold” from “buy” and slashed its price target to $11 from $35 after the company withdrew the BLA for its Viaskin peanut allergy treatment after a meeting with the FDA. The stock closed at $14.15 on Dec. 19.

Read More
Stephen Kilmer
HCW cuts Advaxis to neutral and removes PT

H.C. Wainwright downgraded Advaxis (NASDAQ:ADXS) to “neutral” from “buy” and removed its price target after Amgen terminated a development and collaboration agreement on ADXS-NEO, Advaxis’ personalized neoantigen-targeting therapy. The stock closed at 23 cents on Dec. 17.

Read More
Stephen Kilmer
Roth ups Arch Therapeutics PT to $3 from $2.10

Roth Capital Partners raised its price target for Arch Therapeutics (OTCQB:ARTH) to $3 from $2.10 after the FDA cleared the company’s AC5 Topical Gel for use in partial and full-thickness skin wounds, such as pressure sores, leg ulcers, diabetic ulcers and surgical wounds. The stock closed at 59 cents on Dec. 17.

Read More
Stephen Kilmer